Lazanda (fentanyl nasal spray – West Therapeutic Development) — Medica

Initial criteria

• Patient meets BOTH of the following (A and B):
• A) Patient meets ONE of the following conditions (i or ii):
• i. Patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting; OR
• ii. Patient is unable to take two other short-acting narcotics secondary to allergy or severe adverse events;
• B) Patient is on or will be on an oral or transdermal long-acting narcotic, or the patient is on an intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotic.

Approval duration

1 year